In This Story
Anixa Biosciences Inc. (ANIX-3.47%) has submitted its Form 10-K filing for the fiscal year ended October 31, 2024.
The filing details the company's focus on developing therapies and vaccines for oncology, including a chimeric endocrine receptor-T cell therapy for ovarian cancer and vaccines for breast and ovarian cancers.
Anixa's subsidiary, Certainty Therapeutics, Inc., is conducting clinical trials for its CAR-T technology in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc.
The company has entered into a Joint Development and Option Agreement with The Cleveland Clinic Foundation to develop additional cancer vaccines.
Anixa reported no revenue for the fiscal year 2024, compared to $210,000 in fiscal year 2023 from a licensing agreement related to its encrypted audio/video conference calling technology.
Research and development expenses increased to approximately $6.4 million in fiscal year 2024, up from $4.8 million in fiscal year 2023, primarily due to increased activity in its CAR-T and vaccine development programs.
General and administrative expenses rose to approximately $7.4 million in fiscal year 2024 from $6.3 million in fiscal year 2023.
Anixa reported a net loss of approximately $12.7 million for fiscal year 2024, compared to a net loss of $9.9 million in fiscal year 2023.
The company had cash, cash equivalents, and short-term investments totaling approximately $19.9 million as of October 31, 2024.
Anixa anticipates that its existing cash, cash equivalents, and short-term investments will be sufficient to fund its activities for at least the next twelve months.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Anixa Biosciences Inc. annual 10-K report dated January 10, 2025. To report an error, please email earnings@qz.com.